recipientsProspective Evaluation of the Efficacy of Budesonide/Formoterol (Symbicort®) in Bronchiolitis Obliterans in Allogeneic Haematopoietic Stem Cell Transplantation (AHSCT) Recipients
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 32
- 试验地点
- 1
- 主要终点
- The primary endpoint is based on pulmonary function tests (PFT): the absolute variation of FEV1 after 1 month of treatment will be assessed.
研究概览
简要总结
The usual treatment for obstructive airway disease (OAD) after allogeneic hematopoietic stem cell transplantation (AHSCT) , which is related to graft versus host disease (GVHD), consists of intensification of systemic immunosuppressive therapy.
详细描述
Although it has not been evaluated prospectively, the usual treatment for obstructive airway disease (OAD) after allogeneic hematopoietic stem cell transplantation (AHSCT) , which is related to graft versus host disease (GVHD), consists of intensification of systemic immunosuppressive therapy. However, this treatment has a limited efficacy and is associated with a significant number of serious adverse effects, particularly infectious. Alternative treatments are therefore necessary.We have retrospectively reported clinical and functional improvement in patients with OAD following AHSCT treated with inhaled budesonide/formoterol combination.These encouraging results need to be confirmed by the present randomised, prospective double-blind trial. This study is therefore designed to evaluate the efficacy of budesonide/formoterol versus placebo in patients with moderate to severe OAD, not requiring initiation or intensification of systemic immunosuppressive therapy for extra thoracic GVHD.
Inclusion criteria modified according to amendment of 02/11/2009
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 16 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥16 years.
- •Previous normal PFTs available.
- •Absence of extrathoracic GVH disease justifying initiation or intensification of systemic immunosuppressive therapy.
- •Respiratory signs present for less than 6 months.
- •AHSCT recipients who have developed moderate to severe bronchiolitis obliterans, defined by reduction of FEV1/VC below the 5th percentile of predicted normal or < 80% of predicted, with FEV1 < 80% of predicted and ≥ 40% of predicted, not reversible after inhalation of short-acting beta-2 agonist. AHSCT recipients with FEV1 < 80% of predicted and ≥ 40% of predicted, not reversible after inhalation of short-acting beta-2 agonist and TLC ≥ 80% of predicted.
- •Respiratory symptoms related to obstructive lung disease present for at least 6 months.
- •Negative respiratory microbiology work-up.
- •Informed consent signed by the patient or both parents of a minor.
排除标准
- •Extrathoracic graft versus host reaction justifying initiation or intensification of systemic immunosuppressive therapy.
- •Use of inhaled bronchodilator and/or corticosteroid therapy at the time of inclusion.
- •Known intolerance to inhaled bronchodilators and/or corticosteroids and/or lactose.
- •Personal or donor history of asthma.
- •Active smoking
- •FEV1 < 40% of predicted normal or ≥ 80% of predicted normal or PO2 < 50 mmHg.
- •Documented respiratory tract infection.
- •Pregnancy.
- •Absence of effective contraception during the trial.
- •Not covered by French national health insurance.
研究组 & 干预措施
1
Patients with OAD will receive Symbicort® at the dose of two puffs morning and evening, each delivering 400/12 µg of budesonide/formoterol. Symbicort® will be administered by inhalation using the Turbuhaler (TH) system
干预措施: Formoterol/Budesonide (Drug)
2
Patients with OAD will receive lactose as a placebo, administered by inhalation using the Turbuhaler (TH) system
干预措施: lactose (Drug)
结局指标
主要结局
The primary endpoint is based on pulmonary function tests (PFT): the absolute variation of FEV1 after 1 month of treatment will be assessed.
时间窗: 1 month
次要结局
- Improvement or stabilisation of FEV1; Prevalence of improvement of FEV1 by at least 200 ml and 12% at 1 month compared to baseline; Variation of FEF 25-75% and vital capacity; Quality of life measurement; Evaluation of the clinical score(1, 6 and 7 months)